Skip to Content
Merck
  • Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.

Orexin-A suppresses postischemic glucose intolerance and neuronal damage through hypothalamic brain-derived neurotrophic factor.

The Journal of pharmacology and experimental therapeutics (2012-11-03)
Shinichi Harada, Yui Yamazaki, Shogo Tokuyama
ABSTRACT

Orexin-A (a glucose-sensing neuropeptide in the hypothalamus) and brain-derived neurotrophic factor (BDNF; a member of the neurotrophin family) play roles in many physiologic functions, including regulation of glucose metabolism. We previously showed that the development of postischemic glucose intolerance is one of the triggers of ischemic neuronal damage. The aim of this study was to determine whether there was an interaction between orexin-A and BDNF functions in the hypothalamus after cerebral ischemic stress. Male ddY mice were subjected to 2 hours of middle cerebral artery occlusion (MCAO). Neuronal damage was estimated by histologic and behavioral analyses. Expression of protein levels was analyzed by Western blot. Small interfering RNA directed BDNF, orexin-A, and SB334867 [N-(2-methyl-6-benzoxazolyl)-N'-1,5-naphthyridin-4-yl urea; a specific orexin-1 receptor antagonist] were administered directly into the hypothalamus. The level of hypothalamic orexin-A, detected by immunohistochemistry, was decreased on day 1 after MCAO. Intrahypothalamic administration of orexin-A (1 or 5 pmol/mouse) significantly and dose-dependently suppressed the development of postischemic glucose intolerance on day 1 and development of neuronal damage on day 3. The MCAO-induced decrease in insulin receptor levels in the liver and skeletal muscle on day 1 was recovered to control levels by orexin-A, and this effect of orexin-A was reversed by the administration of SB334867 as well as by hypothalamic BDNF knockdown. These results suggest that suppression of postischemic glucose intolerance by orexin-A assists in the prevention of cerebral ischemic neuronal damage. In addition, hypothalamic BDNF may play an important role in this effect of orexin-A.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type VII, ammonium sulfate suspension, ≥200 units/mg protein
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type IX, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from baker′s yeast (S. cerevisiae), Type XV, lyophilized powder, 200-400 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, Type XXIII, ammonium sulfate suspension, 550-1,100 units/mg protein (biuret), ≥2.0 mg/mL Biuret
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, lyophilized powder, ≥550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, recombinant, expressed in E. coli, ammonium sulfate suspension, ≥550 units/mg protein (biuret)
Sigma-Aldrich
Glucose-6-phosphate Dehydrogenase from Leuconostoc mesenteroides, lyophilized powder, >= 550 units/mg protein (biuret)